Not a good buy right now for an impatient entry: price (93.85 pre-market) is below key support S1 (94.672) while momentum (MACD) is still worsening.
Setup is “oversold but falling”: RSI_6 ~22 suggests potential bounce risk, but no confirmation signal and downside to S2 (91.935) is still plausible.
Options positioning is mildly bullish (put/call ratios < 1), but activity is very small and IV is elevated into earnings, which can make timing unfavorable.
Best read today: HOLD / avoid fresh buys until the stock reclaims ~95 (back above S1) and ideally pushes toward the pivot ~99.10 with improving momentum.
Technical Analysis
Trend/Momentum: MACD histogram -0.941 and negatively expanding = bearish momentum is strengthening.
RSI: RSI_6 at ~22 is technically oversold (despite the label), which can support a short-term bounce, but it is not a buy signal on its own.
Moving averages: converging MAs = indecision; combined with bearish MACD suggests the down move hasn’t clearly ended.
Key levels (pre-market 93.85): Below S1 94.672 (near-term bearish). Next support S2 91.935. Overhead pivot resistance 99.103, then R1 103.535.
Pattern-based forward view: Similar-pattern stats imply modest upside next day/week, but a negative next-month drift (-1.87%), aligning with the current bearish momentum.
No analyst rating/price target change data was provided in the dataset, so no confirmed recent upgrades/downgrades or target revisions can be summarized.
Wall St pro/con view cannot be validated from the given data; based on fundamentals alone, pros are strong growth and high margins, while the main con right now is the weakening technical setup into earnings.
Wall Street analysts forecast IRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99 USD with a low forecast of 98 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast IRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99 USD with a low forecast of 98 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 94.540
Low
98
Averages
99
High
100
Current: 94.540
Low
98
Averages
99
High
100
Roth Capital
Buy
maintain
$90 -> $98
AI Analysis
2025-11-04
Reason
Roth Capital
Price Target
$90 -> $98
AI Analysis
2025-11-04
maintain
Buy
Reason
Roth Capital raised the firm's price target on iRadimed to $98 from $90 and keeps a Buy rating on the shares after its Q3 earnings beat. Legacy pump sales remain strong despite the planned full launch of the next generation version in Q1, monitor sales accelerated in the quarter, and there could be nice uplift from the cross-selling the next gen pump into non-user hospitals, the analyst tells investors in a research note.
Lake Street
Buy
maintain
$75 -> $100
2025-11-03
Reason
Lake Street
Price Target
$75 -> $100
2025-11-03
maintain
Buy
Reason
Lake Street raised the firm's price target on iRadimed to $100 from $75 and keeps a Buy rating on the shares after a top and bottom line beat with revenue and EPS guidance increased in Q3. While acknowledging that shares trade at a premium valuation, the firm sees a record backlog providing near-term visibility and the new 3870 IV Pump launch driving growth acceleration in 2026, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IRMD
